Search hospitals > Illinois > Washington

Illinois CancerCare - Washington

Claim this profile
Washington, Illinois 61571
Global Leader in Cancer
Global Leader in Adenocarcinoma
Conducts research for Breast Cancer
Conducts research for Tumors
Conducts research for Lung Cancer
139 reported clinical trials
1 medical researcher
Photo of Illinois CancerCare - Washington in WashingtonPhoto of Illinois CancerCare - Washington in WashingtonPhoto of Illinois CancerCare - Washington in Washington

Summary

Illinois CancerCare - Washington is a medical facility located in Washington, Illinois. This center is recognized for care of Cancer, Adenocarcinoma, Breast Cancer, Tumors, Lung Cancer and other specialties. Illinois CancerCare - Washington is involved with conducting 139 clinical trials across 285 conditions. There are 1 research doctors associated with this hospital, such as Bryan A. Faller.

Area of expertise

1Cancer
Global Leader
Illinois CancerCare - Washington has run 64 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage I
2Adenocarcinoma
Global Leader
Illinois CancerCare - Washington has run 23 trials for Adenocarcinoma. Some of their research focus areas include:
Stage IV
Stage III
HER2 negative

Top PIs

Clinical Trials running at Illinois CancerCare - Washington

Breast Cancer
Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Prostate Cancer
Gastric Cancer
Bladder Cancer
Gastroesophageal Junction Adenocarcinoma
Esophageal Cancer
Melanoma
Image of trial facility.

Shorter Chemo-Immunotherapy Without Anthracyclines

for Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Durvalumab + Chemotherapy

for Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Illinois CancerCare - Washington?
Illinois CancerCare - Washington is a medical facility located in Washington, Illinois. This center is recognized for care of Cancer, Adenocarcinoma, Breast Cancer, Tumors, Lung Cancer and other specialties. Illinois CancerCare - Washington is involved with conducting 139 clinical trials across 285 conditions. There are 1 research doctors associated with this hospital, such as Bryan A. Faller.